Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
August 08, 2017 07:30 ET
|
Esperion Therapeutics, Inc.
– 1002-038 Study Meets Primary Endpoint With a Robust 64% LDL-C Lowering Efficacy –– Clinically Relevant 48% hsCRP Reduction –– The Combination Therapy Was Observed to be Safe and Well-Tolerated ––...
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
March 07, 2017 08:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on developing and commercializing convenient, complementary,...